Voyager Therapeutics, Inc. (VYGR) Operating cash flow 2016–2025
Voyager Therapeutics, Inc. (VYGR) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$132.5MFY2025 · since FY2016: -$42.5M → -$132.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$132.5M | -765.2% |
| FY2024 | -$15.3M | -119.6% |
| FY2023 | $77.9M | +722.9% |
| FY2022 | -$12.5M | +76.6% |
| FY2021 | -$53.5M | +44.7% |
| FY2020 | -$96.7M | -298.7% |
| FY2019 | $48.7M | +406.3% |
| FY2018 | -$15.9M | +74.1% |
| FY2017 | -$61.4M | -44.4% |
| FY2016 | -$42.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Net marginVYGR Gross profitVYGR Gross marginVYGR Operating incomeVYGR Operating marginVYGR Free cash flowVYGR Capital expendituresVYGR Return on equityVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Total liabilitiesVYGR Shareholders’ equityVYGR overview →